The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome
https://doi.org/10.18087/cardio.2400
Abstract
Aim. To evaluate clinical value copeptin and matrix metalloproteinases in men with acute coronary syndrome (ACS). Materials and methods. the study included 152 men with ACS. After evaluation of the traditional markers of myocardial damage, the patients were divided into 2 groups: the first group included patients with myocardial infarction (MI) - 84 people, the average age was 56.6±1.0 years, the second - with unstable angina (UA) - 68 at the age of 61,4±1.2 years. All patients at admission and after 6 hours and on day 6 of hospitalization were evaluated for the level of CPK MB, troponin I, copeptin, MMP-1, MMP-2, MMP-7, MMP-9 and TIMP-1. Results. Concentration of copeptin at admission in patients with it is 3.5 times higher than in the group with UA and significantly higher than that of control group. To 6-th day of hospitalization, the concentration of copeptin reduced, but nonetheless remains significantly higher than in the control group (0,9±0,1 vs. 0.2±0,0, p=0.000) without significant differences with group UA. The level of MMP-1 and MMP-2 in patients with MI and UA at admission higher than in the control group, and in case of MI these levels are significantly higher than in case of UA. Conclusion. The obtained data indicates the possibility of using copeptin as a marker of myocardial damage. Additionally, it indicates myocardial damage an increase in the level of MMP-1, MMP-2 and MMP-7
About the Authors
O. S. Tanana
Altai regional cardiological dispensary
Russian Federation
Russian Federation
I. A. Sukmanova
Altai State Medical University
Russian Federation
Russian Federation
I. V. Ponomarenko
Altai regional cardiological dispensary
Russian Federation
Russian Federation
References
1. O'Donoghue M.L., Morrow D.A., Cannon C.P., Jarolim P., Desai N.R., Sherwood M.W. et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016; 5 (5). DOI: 10.1161/JAHA.115.002586.
2. Sinning C., Ojeda F., Zeller T., Zengin E., Rupprecht H.-J., Lackner K.-. et al. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress. Can J Cardiol. 2016; 32 (12): 1470-7. DOI: 10.1016/j.cjca.2016.05.010.
3. Kip M.M., Steuten L.M., Koffijberg H., IJzerman M.J., Kusters R. Using expert elicitation to estimate the potential impact of improved diagnostic performance of laboratory tests: a case study on rapid discharge of suspected non-ST elevation myocardial infarction patients. J Eval Clin Pract. 2016; DOI: 10.1111/jep.12626.
4. Ahmad T., Wang T., O'Brien E.C., Samsky M.D., Pura J.A., Lokhnygina Y. et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. JACC Heart Fail. 2015; 3 (1): 30-9. DOI: 10.1016/j.jchf.2014.06.013.
5. Mueller M., Giannitsis E., Katus H.A. [Essential cardiac biomarkers in myocardial infarction and heart failure]. Herz. 2014; 39 (6): 727-739; quiz 740-741. DOI: 10.1007/s00059-014-4136-8.
6. Thelin J., Melander O., Öhlin B. Early rule-out of acute coronary syndrome using undetectable levels of high sensitivity troponin T. Eur Heart J Acute Cardiovasc Care. 2015; 4 (5): 403-9. DOI: 10.1177/2048872614554107.
7. Sörensen N.A., Shah A.S., Ojeda F.M., Peitsmeyer P., Zeller T., Keller T. et al. High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2016; 5 (6): 419-27. DOI: 10.1177/2048872615611108.
8. Vafaie M., Slagman A., Möckel M., Hamm C., Huber K., Müller C. et al. Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome. Am J Med. 2016; 129 (3): 274-282.e2. DOI: 10.1016/j.amjmed.2015.10.016.
9. Smaradottir M.I., Ritsinger V., Gyberg V., Norhammar A., Näsman P., Mellbin L.G. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diab Vasc Dis Res. 2017; 14 (2): 69-76. DOI: 10.1177/1479164116664490.
10. Tasevska I., Enhörning S., Persson M., Nilsson P.M., Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016; 102 (2): 127-32. DOI: 10.1136/heartjnl-2015-308183.
11. Searle J., Slagman A., Stockburger M., Vollert J.O., Müller C., Muller R. et al. Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J Acute Cardiovasc Care. 2015; 4 (5): 393-402. DOI: 10.1177/2048872614554197.
12. Jacobs L.H.J., van Borren M., Gemen E., van Eck M., van Son B., Glatz J.F.C. et al. Rapidly rule out acute myocardial infarction by combining copeptin and heart-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015; 52 (Pt 5): 550-61. DOI: 10.1177/0004563215578189.
13. Savic-Radojevic A., Pljesa-Ercegovac M., Matic M., Simic D., Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017; 79: 93-152. DOI: 10.1016/bs.acc.2016.09.002.
14. Stallone F., Schoenenberger A.W., Puelacher C., Rubini Gimenez M., Walz B., Naduvilekoot Devasia A. et al. Incremental value of copeptin in suspected acute myocardial infarction very early after symptom onset. Eur Heart J Acute Cardiovasc Care. 2016; 5 (5): 407-15. DOI: 10.1177/2048872616641289.
15. Hamed G.M., Fattah M.F.A. Clinical Relevance of matrix metallopro-teinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost. 2015; 21 (8): 705-11. DOI: 10.1177/1076029614567309.
Review
For citations:
Tanana O.S., Sukmanova I.A., Ponomarenko I.V. The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome. Kardiologiia. 2017;57(3S):32-39. (In Russ.) https://doi.org/10.18087/cardio.2400
Views:
680
Email this article 
Post a Comment 
